Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gary Curhan
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Allena Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research focuses on oxalate as a potential contributor to the progression and complications of chronic kidney disease (CKD) in the underlying mechanisms of CKD. The research is on the underlying mechanisms of chronic kidney disease (CKD) pathogenesis, progression, and complications. It tests the hypothesis that oxalate, a toxic terminal metabolite that accumulates in all forms of CKD, contributes to the progression and complications of CKD. Allena Pharmaceuticals, Inc., is developing a product that seeks to reduce the burden of the accumulation of oxalate. The Committee on Outside Activities review panel evaluated Dr. Curhan’s financial interest in connection with these research projects and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Oxalate and the Progression and Complications of CKD
Chronic kidney disease (CKD) can be a progressive disease that leads to kidney failure, cardiovascular complications, and early mortality. In this proposal we will test whether higher levels of plasma and urine oxalate-a toxic terminal metabolite that accumulates in patients with CKD-are associated with a higher risk of kidney failure and cardiovascular disease events. Identification of oxalate as a risk factor and potential mediator of tissue injury in CKD may lead to the incorporation of oxalate measurements into the routine evaluation of CKD patients and focus efforts to test therapies to limit oxalate absorption or generation.
Filed on September 11, 2017.
Tell us what you know about Gary Curhan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Gary Curhan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Gary Curhan | Brigham and Women's Hospital | Conflict of Interest | Allena Pharmaceuticals, Inc. | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.